Associate Professor of Internal Medicine, Washington University School of Medicine
Oncology
Dr. Douglas R. Adkins, MD
|
|
Give Review
Douglas Adkins practices Oncology. He went to medical school at Wright State University Boonshoft School of Medicine. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Douglas Adkins is a published doctor and has 27 publications published. The lastest was: 'Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.' He accepts Medicare.
Publications
- Improved clinical trial enrollments for uterine leiomyoSarcoma patients after gynecologic oncology partnership with a Sarcoma center.
- Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angioSarcoma.
- RTOG 0522: Huge Investment in Patients and Resources and No Benefit With Addition of Cetuximab to Radiotherapy-Why Did This Occur?
- Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck.
- Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous Cell carcinoma of the head and neck.
- Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit.
- Response to: 'Pre-medications for cetuximab induced infusion reactions-Commentary'
- Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.
- Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous Cell carcinoma is safe and improves quality of life.
- Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous Cell carcinoma of the head and neck.
- Risk-stratified patients with resectable soft tissue Sarcoma benefit from epirubicin-based adjuvant chemotherapy.
- Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: A critical Analysis of patterns and outcomes.
- Antiangiogenic agents for nonmalignant Brain tumors.
- Prognostic value of (18)F-FDG PET metabolic parameters in oropharyngeal squamous Cell carcinoma.
- A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced s...
- Squamous cell Cancer of the head and neck with distant metastasis at presentation.
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
- Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal Cancer: outcomes and prognostic factors.
- Total body irradiation before an allogeneic stem Cell transplantation: is there a magic dose?
- Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous Cell carcinoma.
- Long-term remissions in patients with myelodysplastic syndrome and secondary Acute myelogenous leukemia undergoing allogeneic transplantation following a reduced inten...
- Unrelated donor marrow transplantation for B-cell chronic lymphocytic Leukemia after using myeloablative conditioning: results from the Center for International Blood ...
- Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-Cell transplantation for non-Hodgkin's lymphoma.
- Recent advances in allogeneic hematopoietic stem-Cell transplantation.
- Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous Cell carcinoma.
- Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Schools
Wright State University Main Campus
University Tx Hsc
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas Health Science Center -
Wright State University Boonshoft School of Medicine
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1164440616 | |
| NPPES Provider LastName | ADKINS | |
| NPPES Provider FirstName | DOUGLAS | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 931.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 156.0 | |
| Percent Opioid Claims | 16.76 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164440616 |
| Last Name Of The Provider | ADKINS |
| First Name Of The Provider | DOUGLAS |
| View All |
Similar Doctors
|
|
Dr. Matthew J. Ellis, MD |
|
|
Dr. Vikram C. Gorantla, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Camille N. Abboud, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Cynthia X. Ma, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andres S. Carden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Moriconi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea Wang-Gillam, MD |
|
|
Dr. Sagun D. Goyal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine N. Weilbaecher, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Amanda Cashen, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Saiama N. Waqar, MD
This Doctor is OpenDoctor Recommended.
|